The estimated Net Worth of Jack W Callicutt is at least $799 Tausend dollars as of 17 November 2022. Mr. Callicutt owns over 4,000 units of Galectin Therapeutics Inc stock worth over $20,862 and over the last 11 years he sold GALT stock worth over $0. In addition, he makes $778,123 as Chief Financial Officer und Secretary at Galectin Therapeutics Inc.
Jack has made over 9 trades of the Galectin Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of GALT stock worth $5,280 on 17 November 2022.
The largest trade he's ever made was exercising 226,000 units of Galectin Therapeutics Inc stock on 19 June 2018 worth over $971,800. On average, Jack trades about 17,953 units every 143 days since 2013. As of 17 November 2022 he still owns at least 7,614 units of Galectin Therapeutics Inc stock.
You can see the complete history of Mr. Callicutt stock trades at the bottom of the page.
Jack W. Callicutt CPA serves as Chief Financial Officer, Secretary of the Company. From August 2012 through June 2013, Mr. Callicutt was the Chief Financial Officer of REACH Health, Inc., a telemedicine technology company headquartered in Alpharetta, GA. From April 2010 through August 2012, Mr. Callicutt was the Chief Financial Officer of Vystar Corporation, a publicly traded company that holds proprietary technology to remove antigenic proteins from natural rubber latex. Prior to that Mr. Callicutt was Chief Financial Officer of IVOX, Inc., Tikvah Therapeutics and Corautus Genetics, a publicly traded biotechnology company which was developing gene therapy for treatment of cardiovascular disease. Mr. Callicutt previously spent more than fourteen years in public accounting, most recently as a senior manager at Deloitte, where he specialized in technology companies from 1989 to 2003. Mr. Callicutt is a Certified Public Accountant and graduated with honors from Delta State University with a B.B.A. in accounting and computer information systems.
As the Chief Financial Officer und Secretary of Galectin Therapeutics Inc, the total compensation of Jack Callicutt at Galectin Therapeutics Inc is $778,123. There are 1 executives at Galectin Therapeutics Inc getting paid more, with Harold Shlevin having the highest compensation of $1,306,510.
Jack Callicutt is 53, he's been the Chief Financial Officer und Secretary of Galectin Therapeutics Inc since 2018. There are 13 older and 6 younger executives at Galectin Therapeutics Inc. The oldest executive at Galectin Therapeutics Inc is Gilbert Omenn, 79, who is the Independent Director.
Jack's mailing address filed with the SEC is C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS, GA, 30071.
Over the last 14 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr und Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.
galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much
Galectin Therapeutics Inc executives and other stock owners filed with the SEC include: